Explore groundbreaking studies, clinical trial updates, and emerging technologies shaping the future of cancer treatment.
Explore how palbociclib, the first CDK4/6 inhibitor, is transforming treatment for hormone receptor-positive breast cancer through precision targeting of the cell cycle.